Vertex Pharmaceuticals Inc. Stock
Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Vertex Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | 0.910% | 5.368% | 6.094% | 23.188% | 5.637% | 123.831% | 162.048% |
| Exact Sciences | -0.880% | -13.913% | -27.532% | -30.698% | -27.543% | -39.029% | -40.419% |
| Incyte Corp. | 0.200% | -1.382% | -3.846% | -15.378% | -13.201% | -26.624% | -30.935% |
| Regeneron Pharmaceuticals Inc. | 0.870% | 1.619% | 3.743% | 32.396% | 13.304% | 118.446% | 224.802% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Vertex Pharmaceuticals Inc (VRTX) has been growing consistently in the Biotechnology & Medical Research industry in recent years, as indicated by its financial statements. The company's financials, from its balance sheets to its income and cash flow statements, exhibit a strong growth in its assets, revenues, and profits.
Vertex has shown significant growth in total assets, as evidenced by a consistent increase from almost $11.75 billion in 2020 to over $18.15 billion in 2022. This growth highlights the company's strong financial position, enabling it to capitalize on investment opportunities and fuel further expansion.
The total revenue Vertex generated also increased from over $6.2 billion in 2020 to nearly $8.9 billion in 2022. The steady rise in sales is a positive sign for investors and points to the company's successful execution of its growth strategy.
Comments
News
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 8% from a peak they reached this January. The price action doesn't jive with the biopharmaceutical company's cash flows and the
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q1 2024 Earnings CallMay 06, 2024, 4:30 p.m. ET
Operator
Source Fool.com
2 Fantastic Growth Stocks to Buy Right Now
While some stocks have responded to the 2024 bull market better than others, an abundance of stocks have followed this rising tide. There's no predicting how long this next bull market will last